 |
| Global Leigh Syndrome Treatment Market Growth |
The global Leigh syndrome treatment market consists of therapies for an
acquired neurological disorder typically occurring in infancy or early
childhood due to defects in mitochondrial DNA or nuclear genes. Symptoms
include developmental delay, muscle weakness or hypotonia, problems with
movement, seizures and loss of earlier abilities. Current treatments include
providing dietary supplements and respiratory support. Gene therapy is emerging
as a promising approach to replace missing or defective genes with functional
copies to potentially cure the underlying genetic defects.
The Global Leigh Syndrome Treatment Market is estimated to be valued at US$ 272.9 million in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period
from 2024 to 2031.
Key Takeaways
Key players operating in the Global
Leigh Syndrome Treatment Market Growth are Abliva AB, PTC Therapeutics,
VAKS Pharma, MITOCH, Medley Pharmaceuticals Ltd., Khondrion BV, OMEICOS
THERAPEUTICS GMBH. , Edison Pharmaceuticals, Inc. , Dainippon Sumitomo Pharma
Co. Ltd., Taysha GTx, PicnicHealth (AllStripes), Takeda Pharmaceutical Company
, Biogen, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and MECOSON
LABS PRIVATE LIMITED.
The growing demand in the market can be attributed to rising Leigh syndrome
disease prevalence and growing diagnosis rates. In addition, increased research
funding for rare diseases and continuous pipeline developments are further
fueling market growth.
Global expansion of key players through partnerships and acquisitions have
helped strengthen their market presence. Manufacturers are also focusing on
emerging markets in Asia Pacific and Middle East & Africa using new product
launches and approvals to tap growth opportunities in these regions.
Market Key Trends
One of the key trends gaining traction in the global Leigh syndrome treatment
market is the increased focus on developing advanced gene therapies. Numerous
gene therapy candidates are currently under research which can precisely target
the underlying genetic defects. If successfully developed, these gene therapies
have the potential to significantly alter the treatment landscape in the coming
years. Increased investments by industry players in gene therapy research and
partnerships with clinical-stage biotech companies indicate growing optimism
around these novel treatment approaches.
Porter’s Analysis
Threat of new entrants: The global Leigh syndrome treatment market has moderate
threats from the new entrants due to high initial capital requirements and
established brand loyalty of existing key players in the market.
Bargaining power of buyers: The buyers have low bargaining power in the market
due to limited treatment options available for Leigh syndrome.
Bargaining power of suppliers: The suppliers have moderate bargaining power in
the market due to availability of substitutable raw materials.
Threat of new substitutes: Currently, there is no direct substitute available
for the treatment of Leigh syndrome.
Competitive rivalry: The global market experiences high competitive rivalry
among the key existing players to gain higher market share.
Geographical regions where market in terms of value is concentrated:
North America region holds the major share in the global Leigh syndrome
treatment market in terms of value owing to well-established healthcare
infrastructure and availability of advanced treatment options in countries like
the US and Canada.
Another fastest growing region for the given market:
Asia Pacific region is expected to witness the fastest growth in the coming
years majorly driven by increasing healthcare expenditure, rising awareness
about rare diseases, and growing research activities in emerging economies like
China and India.